201286-69-3

Basic information

• Product Name: 1H-Indole-6-carboxylicacid,3-methyl-(9CI)
• Synonyms: 1H-Indole-6-carboxylicacid,3-methyl-(9CI);1H-INDOLE-6-CARBOXYLIC ACID, 3-METHYL-;3-Methyl-1H-indole-6-carboxylic acid
• CAS NO: 201286-69-3
• Molecular Formula: C₁₀H₉NO₂
• Molecular Weight: 175.19
• Product Categories: INDOLE
• Mol File: 201286-69-3.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: 1H-Indole-6-carboxylicacid,3-methyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Indole-6-carboxylicacid,3-methyl-(9CI)(201286-69-3)
• EPA Substance Registry System: 1H-Indole-6-carboxylicacid,3-methyl-(9CI)(201286-69-3)

Safety Data

• Hazardous Substances Data: 201286-69-3(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
1H-Indole-6-carboxylic acid, 3-methyl-(9CI) is used as a key intermediate in organic synthesis for the production of various organic compounds. Its unique structure allows for versatile chemical reactions, making it a valuable building block in the synthesis of complex molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 1H-Indole-6-carboxylic acid, 3-methyl-(9CI) is utilized as a precursor for the synthesis of bioactive molecules. Its ability to be modified and incorporated into larger molecular structures contributes to the development of new drugs with potential therapeutic effects.
Used in Natural Products:
1H-Indole-6-carboxylic acid, 3-methyl-(9CI) can also be found in some natural products, where it may contribute to the biological activity or properties of these products. Its presence in natural sources highlights its potential for use in the development of natural-based pharmaceuticals and other applications.
Overall, 1H-Indole-6-carboxylic acid, 3-methyl-(9CI) is an important chemical in organic chemistry with a wide range of potential applications, including organic synthesis, pharmaceutical development, and natural product research. Its unique structure and properties make it a valuable compound for further exploration and utilization in various industries.

Upstream product

• 184151-49-3 methyl 3-methylindole-6-carboxylate 
• 1219741-50-0 6-bromo-3-methyl-1H-indole 
• 17826-04-9 6-bromo-1H-indole-3-carbaldehyde 
• 50820-65-0 indole-6-carboxylic acid methyl ester 
• 133831-28-4 methyl 3-formyl-6-indolecarboxylate 

Relevant articles and documents

INHIBITORS OF ENL/AF9 YEATS

Methods and compositions for treating leukemia are disclosed. Acylated 6-aminoindoles, acylated 6-aminopyrrolopyridines and acylated 3-aminopyrrolo[3,2-c]pyridazines of the following formula inhibit ENL/AF9 YEATS and are therefore useful for treating leukemia.

HEPATITIS B CORE PROTEIN MODULATORS

The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound of formula:

Substituted azabicyclic compounds

This invention is directed to certain physiologically active compounds of formula (I) wherein represents a bicyclic ring system, of about 10 to about 13 ring members, in which the ring is an azaheterocycle, and the ring represents an azaheteroaryl ring, or an optionally halo substituted benzene ring; and N-oxides thereof, and their prodrugs, and pharmaceutically acceptable salts and solvates of the compounds of formula (I) and N-oxides thereof, and their prodrugs. Such compounds inhibit the production or physiological effects of TNF and inhibit cyclic AMP phosphodiesterase. The invention is also directed to pharmaceutical compositions comprising compounds of formula (I), their pharmaceutical use and methods for their preparation.

The synthesis and biological evaluation of a novel series of indole PDE4 inhibitors I

This communication describes the synthesis and in vitro evaluation of a novel potent series of phosphodiesterase type (IV) (PDE4) inhibitors. The compounds described contain an indole moiety which replaces the 'rolipram- like' 3-methoxy-4-cyclopentoxy motif. Several of the compounds presented possess low nanomolar IC50's for PDEIV inhibition. In vivo activities determined from measurement of serum TNF-α levels in LPS challenged mice (mouse endotoxemia model) are also reported.